<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200576</url>
  </required_header>
  <id_info>
    <org_study_id>10225</org_study_id>
    <nct_id>NCT01200576</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar</brief_title>
  <official_title>A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marie Stopes International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This one-year observational study will monitor the contraceptive effectiveness, safety and
      acceptability of Zarin during the first year of use after the method has been approved for
      public use in Madagascar. It will be implemented by Marie Stopes Madagascar with technical
      support from Marie Stopes International and FHI. 300 women of reproductive age who selected
      Zarin as their primary method of contraception will be enrolled in the study at the MSM
      outreach sites and static clinics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This one-year observational study will monitor the contraceptive effectiveness, safety and
      acceptability of Zarin during the first year of use after the method has been approved for
      public use in Madagascar. It will be implemented by Marie Stopes Madagascar with technical
      support from Marie Stopes International and FHI. 300 women of reproductive age who selected
      Zarin as their primary method of contraception will be enrolled in the study at the MSM
      outreach sites and static clinics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The cumulative probability of pregnancy through one year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and incidence rate of adverse events</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and incidence rates of immediate and delayed complications associated with insertion or removal</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The cumulative probability of early discontinuation through one year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for discontinuation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">621</enrollment>
  <condition>Long-term and Permanent Contraceptive Methods</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        healthy women of any age
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be a participant of the MSM service evaluation and continue using Zarin at 3 months

          -  agree at the time of Zarin insertion to be contacted regarding an opportunity to
             participate in more research related to the implant

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Hanitriniaina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marie Stopes International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen Hopkins</last_name>
    <role>Study Chair</role>
    <affiliation>Marie Stopes International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tania Boler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marie Stopes International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Steiner, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marie Stopes Madagascar Mobile Outreach Sites and Static Clinics</name>
      <address>
        <city>Madagascar</city>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Madagascar</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRF: Case Report Form</keyword>
  <keyword>DM: Data Management</keyword>
  <keyword>FHI: FHI (formerly known as Family Health International)</keyword>
  <keyword>IRB: Institutional Review Board</keyword>
  <keyword>IUD: Intra-uterine Device</keyword>
  <keyword>LTPM: Long-term and Permanent Contraceptive Methods</keyword>
  <keyword>MSI: Marie Stopes International</keyword>
  <keyword>MSM: Marie Stopes Madagascar</keyword>
  <keyword>PHSC: Protection of Human Subjects Committee</keyword>
  <keyword>PI: Principal Investigator</keyword>
  <keyword>SAE: Serious Adverse Event</keyword>
  <keyword>Sino-Implant (II)</keyword>
  <keyword>SOP: Standard Operating Procedure</keyword>
  <keyword>Zarin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

